GlassScriptPhysician profile
Joy Stashonsky
NPI 1871079392
$838.47
in general payments reported to CMS, 2019-2025
12 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.72 · 2022: $165 · 2023: $151 · 2024: $121 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.99 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $193.96 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $115.81 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Pulmonx Corporation | $102.89 | 2022-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Grifols USA, LLC | $87.64 | 2022-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $58.87 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $51.83 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.65 | 2021-2022 | |
| Viatris Specialty LLC | $45.58 | 2025 | Yupelri |
| Ethicon INC. | $43.37 | 2023 | Monarch Platform |
| Philips North America LLC | $38.11 | 2025 | Vest Therapy Und |
| Insmed, INC. | $30.89 | 2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $23.87 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Stashonsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.